Form 4: United Therapeutics EVP Sells Shares After Option Exercise

Paul A. Mahon, EVP & General Counsel of United Therapeutics, exercised stock options and sold 11,000 shares of common stock under a pre-arranged 10b5-1 plan.

Summary

• Paul A. Mahon, Executive Vice President and General Counsel of United Therapeutics Corp, exercised 11,000 stock options at an exercise price of $135.42 per share.
• Concurrently, Mahon sold 11,000 shares of common stock in multiple transactions on September 4, 2025.
• The sales were executed at weighted average prices ranging from $379.4737 to $396.54 per share.
• These transactions were conducted pursuant to a Rule 10b5-1 plan, which was established by the reporting person on December 24, 2024.
• Following these transactions, Mahon directly owns 36,781 shares of common stock and 66,000 stock options.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. The transaction is a routine insider sale under a 10b5-1 plan, which is generally viewed as less concerning than an unplanned sale. The executive realized a significant profit, which is positive for the individual but a sale of shares by an executive can sometimes be viewed with slight caution by the market.

Positives

• The transaction was executed under a pre-arranged Rule 10b5-1 plan, indicating a planned and transparent sale, which generally mitigates concerns about opportunistic insider trading.
• The executive realized a significant profit, as the sale prices (ranging from $379.4737 to $396.54) were substantially higher than the option exercise price ($135.42).

Negatives

• An executive selling a significant number of shares, even under a 10b5-1 plan, could be perceived negatively by some investors, potentially signaling a lack of confidence, though this is often a routine part of executive compensation monetization.

Stakeholder Impact

• Shareholders: The sale by an executive, while routine under a 10b5-1 plan, represents a monetization of compensation. It does not inherently signal a change in company fundamentals but is a standard part of executive compensation management.
• Employees: No direct impact on employees is indicated by this filing.

Key Dates

Recommendation

This Form 4 filing reports a routine, pre-scheduled insider transaction (option exercise and sale) by an executive. Such transactions, especially when conducted under a 10b5-1 plan, are typically not indicative of a change in the company's fundamental outlook or a signal for investors to alter their positions. The executive realized a substantial profit, which is a positive for the individual, but the transaction itself does not provide new information warranting a 'buy' or 'sell' recommendation for the stock. Therefore, a 'hold' recommendation is appropriate as the filing does not present new material information to change an existing investment thesis.

Keywords

United Therapeutics, UTHR, Insider Trading, Form 4, Stock Option Exercise, Share Sale, Paul A. Mahon, 10b5-1 Plan, Executive Compensation